Skip to main content

Florida Clears Genetic Technologies' BrevaGen for Sale

NEW YORK (GenomeWeb News) – Genetic Technologies today said that its BrevaGen breast cancer risk stratification test has been cleared by Florida for sale in the state.

The Clinical Laboratory Unit of the Florida Agency for Healthcare Administration cleared the test, following similar action by California authorities in July. This leaves New York as the only state where BrevaGen has not been cleared for sale. Genetic Technologies said that it has submitted to the New York State Department of Health, Clinical Laboratory Evaluation Program to offer Out of State Clinical Laboratory services to New York residents, and its application is being reviewed.

Genetic Technologies received CLIA registration last year for its lab.

Citing statistics from the American Cancer Society, Genetic Technologies said Florida has about 15 percent of all breast cancer incidents in the US. The Australian firm's US subsidiary, Phenogen Sciences, has trained and put into place in Florida a regional business manager, and Genetic Technologies expects to start selling BrevaGen immediately in the state.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.